000			01591 a2200421 4500
005			20250513102246.0
264		0	_c19970210
008			199702s 0 0 eng d
022			_a0162-3109
024	7		_a10.1016/0162-3109(96)00018-5 _2doi
040			_aNLM _beng _cNLM
100	1		_aHecker, M
245	0	0	_aPotentiation of the biological efficacy of bradykinin by ACE inhibitors: a shift in the affinity of the B2 receptor? _h[electronic resource]
260			_bImmunopharmacology _cJun 1996
300			_a93-4 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAngiotensin-Converting Enzyme Inhibitors _xadministration & dosage
650	0	4	_aAnimals
650	0	4	_aBradykinin _xadministration & dosage
650	0	4	_aDrug Synergism
650	0	4	_aIn Vitro Techniques
650	0	4	_aIsoquinolines _xadministration & dosage
650	0	4	_aJugular Veins _xdrug effects
650	0	4	_aOligopeptides _xadministration & dosage
650	0	4	_aPeptidyl-Dipeptidase A _xmetabolism
650	0	4	_aProtease Inhibitors _xadministration & dosage
650	0	4	_aRabbits
650	0	4	_aRamipril _xadministration & dosage
650	0	4	_aRats
650	0	4	_aReceptor, Bradykinin B2
650	0	4	_aReceptors, Bradykinin _xdrug effects
650	0	4	_aTetrahydroisoquinolines
650	0	4	_aVasoconstriction _xdrug effects
700	1		_aBara, A T
700	1		_aBusse, R
773	0		_tImmunopharmacology _gvol. 33 _gno. 1-3 _gp. 93-4
856	4	0	_uhttps://doi.org/10.1016/0162-3109(96)00018-5 _zAvailable from publisher's website
999			_c8850269 _d8850269